- Home
- CGNT vs PLRX Comparison
CGNT vs PLRX Comparison
Compare CGNT & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGNT
- PLRX
- Stock Information
- Founded
- CGNT 2020
- PLRX 2015
- Country
- CGNT Israel
- PLRX United States
- Employees
- CGNT N/A
- PLRX N/A
- Industry
- CGNT Computer Software: Prepackaged Software
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- CGNT Technology
- PLRX Health Care
- Exchange
- CGNT Nasdaq
- PLRX Nasdaq
- Market Cap
- CGNT 657.1M
- PLRX 89.0M
- IPO Year
- CGNT N/A
- PLRX 2020
- Fundamental
- Price
- CGNT $8.46
- PLRX $1.53
- Analyst Decision
- CGNT Hold
- PLRX Hold
- Analyst Count
- CGNT 1
- PLRX 10
- Target Price
- CGNT N/A
- PLRX $3.93
- AVG Volume (30 Days)
- CGNT 289.4K
- PLRX 725.5K
- Earning Date
- CGNT 09-09-2025
- PLRX 11-06-2025
- Dividend Yield
- CGNT N/A
- PLRX N/A
- EPS Growth
- CGNT N/A
- PLRX N/A
- EPS
- CGNT N/A
- PLRX N/A
- Revenue
- CGNT $376,566,000.00
- PLRX N/A
- Revenue This Year
- CGNT $14.94
- PLRX N/A
- Revenue Next Year
- CGNT $9.57
- PLRX N/A
- P/E Ratio
- CGNT N/A
- PLRX N/A
- Revenue Growth
- CGNT 14.04
- PLRX N/A
- 52 Week Low
- CGNT $6.38
- PLRX $1.10
- 52 Week High
- CGNT $11.66
- PLRX $16.10
- Technical
- Relative Strength Index (RSI)
- CGNT 44.61
- PLRX 44.68
- Support Level
- CGNT $8.15
- PLRX $1.66
- Resistance Level
- CGNT $8.81
- PLRX $1.85
- Average True Range (ATR)
- CGNT 0.32
- PLRX 0.13
- MACD
- CGNT -0.02
- PLRX -0.02
- Stochastic Oscillator
- CGNT 21.83
- PLRX 12.20
About CGNT Cognyte Software Ltd.
Cognyte Software Ltd provides security analytics software that empowers governments and enterprises with Actionable Intelligence. Its interface software is designed to help customers accelerate and improve the effectiveness of investigations and decision-making.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.